BRPI0606466A2 - amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos - Google Patents
amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricosInfo
- Publication number
- BRPI0606466A2 BRPI0606466A2 BRPI0606466-3A BRPI0606466A BRPI0606466A2 BR PI0606466 A2 BRPI0606466 A2 BR PI0606466A2 BR PI0606466 A BRPI0606466 A BR PI0606466A BR PI0606466 A2 BRPI0606466 A2 BR PI0606466A2
- Authority
- BR
- Brazil
- Prior art keywords
- disorders
- amylin
- treatment
- agonists
- psychiatric
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title abstract 7
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 title abstract 3
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 title abstract 3
- 229940127438 Amylin Agonists Drugs 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 208000035475 disorder Diseases 0.000 title 1
- 208000011117 substance-related disease Diseases 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 201000009032 substance abuse Diseases 0.000 abstract 1
- 231100000736 substance abuse Toxicity 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66733505P | 2005-03-31 | 2005-03-31 | |
| US66668105P | 2005-03-31 | 2005-03-31 | |
| US67544105P | 2005-04-28 | 2005-04-28 | |
| US76058306P | 2006-01-20 | 2006-01-20 | |
| PCT/US2006/012601 WO2006105527A2 (en) | 2005-03-31 | 2006-03-31 | Amylin and amylin agonists for treating psychiatric diseases and disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0606466A2 true BRPI0606466A2 (pt) | 2009-06-30 |
Family
ID=37054153
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0606466-3A BRPI0606466A2 (pt) | 2005-03-31 | 2006-03-31 | amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos |
| BRPI0609595A BRPI0609595A8 (pt) | 2005-03-31 | 2006-03-31 | composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0609595A BRPI0609595A8 (pt) | 2005-03-31 | 2006-03-31 | composições e métodos para o controle, prevenção e tratamento da obesidade e desordens alimentares |
Country Status (17)
| Country | Link |
|---|---|
| US (7) | US7879794B2 (enExample) |
| EP (5) | EP1888094B1 (enExample) |
| JP (2) | JP5114381B2 (enExample) |
| KR (3) | KR20130122983A (enExample) |
| CN (3) | CN101189021B (enExample) |
| AT (2) | ATE480255T1 (enExample) |
| AU (2) | AU2006230602B2 (enExample) |
| BR (2) | BRPI0606466A2 (enExample) |
| CA (2) | CA2602584A1 (enExample) |
| DE (2) | DE602006008456D1 (enExample) |
| DK (1) | DK1888094T3 (enExample) |
| EA (1) | EA013121B1 (enExample) |
| ES (1) | ES2330671T3 (enExample) |
| IL (1) | IL186200A (enExample) |
| MX (2) | MX2007012237A (enExample) |
| NZ (3) | NZ561936A (enExample) |
| WO (2) | WO2006105345A2 (enExample) |
Families Citing this family (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731947B2 (en) | 2003-11-17 | 2010-06-08 | Intarcia Therapeutics, Inc. | Composition and dosage form comprising an interferon particle formulation and suspending vehicle |
| JP2008500281A (ja) * | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| WO2006083761A2 (en) | 2005-02-03 | 2006-08-10 | Alza Corporation | Solvent/polymer solutions as suspension vehicles |
| US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
| BRPI0606466A2 (pt) | 2005-03-31 | 2009-06-30 | Amylin Pharmaceuticals Inc | amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos |
| WO2007014051A2 (en) * | 2005-07-22 | 2007-02-01 | Amylin Pharmaceuticals, Inc. | Use of amylin and amylin agonists as cardioprotective or myoprotective agents |
| WO2007104789A2 (en) | 2006-03-15 | 2007-09-20 | Novo Nordisk A/S | Amylin derivatives |
| US20090181890A1 (en) * | 2006-03-31 | 2009-07-16 | Amylin Pharmaceuticals , Inc. | Amylin and Amylin Agonists for Treating Psychiatric Diseases and Disorders |
| MX2008012666A (es) * | 2006-03-31 | 2008-10-13 | Amylin Pharmaceuticals Inc | Amilina y agonistas de amilina para tratar enfermedades y trastornos psiquiatricos. |
| ES2351527T3 (es) | 2006-05-30 | 2011-02-07 | Intarcia Therapeutics, Inc | Modulador de flujo en dos piezas con conducto interno para un sistema osmótico de administración. |
| KR101200728B1 (ko) | 2006-08-09 | 2012-11-13 | 인타르시아 세라퓨틱스 인코포레이티드 | 삼투성 전달 시스템 및 피스톤 조립체 |
| WO2008097536A2 (en) | 2007-02-05 | 2008-08-14 | Amylin Pharmaceuticals, Inc. | Compositions and methods for treating psychiatric diseases and disorders |
| RU2440097C2 (ru) | 2007-04-23 | 2012-01-20 | Интарсия Терапьютикс, Инк. | Способ лечения диабета ii типа и ожирения, осмотическое устройство для доставки и способ его изготовления |
| CA2726861C (en) | 2008-02-13 | 2014-05-27 | Intarcia Therapeutics, Inc. | Devices, formulations, and methods for delivery of multiple beneficial agents |
| JP2011525895A (ja) * | 2008-06-25 | 2011-09-29 | ノボ・ノルデイスク・エー／エス | アミリン及びサケカルシトニンの誘導体化ハイブリッドペプチド |
| EP2340261B1 (en) | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
| ES2620610T3 (es) | 2008-12-10 | 2017-06-29 | Glaxosmithkline Llc | Composiciones farmacéuticas de albiglutide |
| AU2010206614B2 (en) * | 2009-01-22 | 2015-03-26 | Keybioscience Ag | Treatment for obesity |
| EP2416797A4 (en) * | 2009-04-10 | 2013-04-24 | Amylin Pharmaceuticals Llc | AMYLINAGONIST COMPOUNDS FOR OXYGEN ANIMAL MICE |
| JP2012524125A (ja) | 2009-04-20 | 2012-10-11 | エルセリクス セラピューティクス インコーポレイテッド | 化学感覚受容体リガンドに基づく治療法 |
| US9901551B2 (en) | 2009-04-20 | 2018-02-27 | Ambra Bioscience Llc | Chemosensory receptor ligand-based therapies |
| US8828953B2 (en) * | 2009-04-20 | 2014-09-09 | NaZura BioHealth, Inc. | Chemosensory receptor ligand-based therapies |
| HRP20171801T1 (hr) | 2009-09-28 | 2017-12-29 | Intarcia Therapeutics, Inc. | Brzo uspostavljanje i/ili brzo završavanje uglavnom stabilne primjene lijeka |
| US8476227B2 (en) | 2010-01-22 | 2013-07-02 | Ethicon Endo-Surgery, Inc. | Methods of activating a melanocortin-4 receptor pathway in obese subjects |
| US9044606B2 (en) | 2010-01-22 | 2015-06-02 | Ethicon Endo-Surgery, Inc. | Methods and devices for activating brown adipose tissue using electrical energy |
| US8691763B2 (en) | 2010-05-04 | 2014-04-08 | Glaxosmithkline Llc | Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection |
| CN102439900A (zh) | 2010-06-28 | 2012-05-02 | 中兴通讯股份有限公司 | 一种全封闭式综合接入系统及其降功耗的方法 |
| SG189444A1 (en) | 2010-10-19 | 2013-05-31 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies |
| HRP20201731T1 (hr) | 2011-01-07 | 2020-12-25 | Anji Pharma (Us) Llc | Terapije na bazi liganda kemozensoričkog receptora |
| US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
| UA125895C2 (uk) * | 2011-06-17 | 2022-07-06 | Ханмі Сайенс Ко., Лтд. | КОН'ЮГАТ, ЩО МІСТИТЬ ПОХІДНУ ОКСИНТОМОДУЛІНУ ТА Fc-ДІЛЯНКУ ІМУНОГЛОБУЛІНУ, ТА ЙОГО ЗАСТОСУВАННЯ |
| KR20230095124A (ko) | 2012-01-06 | 2023-06-28 | 앤지 파마 유에스 엘엘씨 | 바이구아나이드 조성물 및 대사 장애를 치료하는 방법 |
| KR101855242B1 (ko) | 2012-01-26 | 2018-05-09 | 크리스토퍼 제이. 소레스 | 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도 |
| WO2013158928A2 (en) | 2012-04-18 | 2013-10-24 | Elcelyx Therapeutics, Inc. | Chemosensory receptor ligand-based therapies |
| BR102013017626A2 (pt) * | 2013-06-14 | 2015-02-10 | Univ Rio De Janeiro | Bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, uso de bioconjugados não aglomerantes de amilinomiméticos com polietilenoglicol, composições farmacêuticas de baixa toxicidade, adjuvante para a prevenção ou tratamento das doenças, medicamento, método de tratamento ou prevenção de doenças. |
| WO2015017455A1 (en) | 2013-07-30 | 2015-02-05 | Soares Christopher J | Cgrp agonist peptides |
| AR097701A1 (es) * | 2013-09-19 | 2016-04-13 | Zealand Pharma As | Análogos de amilina |
| US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
| US10080884B2 (en) | 2014-12-29 | 2018-09-25 | Ethicon Llc | Methods and devices for activating brown adipose tissue using electrical energy |
| US10092738B2 (en) | 2014-12-29 | 2018-10-09 | Ethicon Llc | Methods and devices for inhibiting nerves when activating brown adipose tissue |
| CN113598842A (zh) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | 植入物放置和移除系统 |
| RU2760007C2 (ru) | 2016-05-16 | 2021-11-22 | Интарсия Терапьютикс, Инк. | Полипептиды, селективные к рецепторам глюкагона, и способы их применения |
| USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
| USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
| EP3506925B1 (en) | 2016-09-02 | 2023-09-06 | Christopher J. Soares | Use of cgrp receptor antagonists in treating glaucoma |
| WO2018129058A1 (en) | 2017-01-03 | 2018-07-12 | Intarcia Therapeutics, Inc. | Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug |
| WO2018132768A1 (en) * | 2017-01-13 | 2018-07-19 | Sanna Pietro P | Methods and compositions for treating hpa hyperactivity |
| EP3628233B1 (en) * | 2018-09-28 | 2021-06-02 | Siemens Healthcare GmbH | Method and system for providing a dose reference value for a patient |
| US11443843B2 (en) | 2019-01-04 | 2022-09-13 | International Business Machines Corporation | Personal customized guidance for treating patients |
| AU2020223284A1 (en) | 2019-02-17 | 2021-09-16 | Neurawell Therapeutics | Compositions and methods for treatment of depression and other disorders |
| CN111700904A (zh) * | 2020-07-31 | 2020-09-25 | 江南大学 | 一种利用酰化淀粉定点释放短链脂肪酸的抗抑郁的方法 |
| EP4366755A4 (en) * | 2021-07-08 | 2025-09-24 | Gila Therapeutics Inc | COMPOSITIONS AND METHODS FOR ACTIVATING A NEURAL RECEPTOR |
| TW202530247A (zh) * | 2023-12-04 | 2025-08-01 | 丹麥商西蘭製藥公司 | 方法 |
| TW202528338A (zh) * | 2023-12-04 | 2025-07-16 | 丹麥商西蘭製藥公司 | 方法 |
Family Cites Families (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3065460D1 (en) | 1979-07-28 | 1983-12-08 | Beecham Group Plc | Benzocycloheptapyrrolealkanoic acids and their derivatives, processes for their preparation and pharmaceutical compositions containing them |
| US4397780A (en) | 1982-02-12 | 1983-08-09 | Armour Pharmaceutical Company | Leucine22 -calcitonin |
| US4401593A (en) | 1982-02-12 | 1983-08-30 | Armour Pharmaceutical Company | Glycine - 8 calcitonin |
| US4414149A (en) | 1983-03-04 | 1983-11-08 | Armour Pharmaceutical Company | Glycine8 -D-arginine24 calcitonin |
| US4495097A (en) | 1983-04-04 | 1985-01-22 | Armour Pharmaceutical Company | Des-serine2 -glycine8 calcitonin |
| US4497731A (en) | 1983-04-04 | 1985-02-05 | Armour Pharmaceutical Company | Glycine 8-des-tyrosine 22 calcitonin |
| US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
| US4597900A (en) | 1983-08-22 | 1986-07-01 | Armour Pharmaceutical Co. | Des2 -glycine8 -des22 -calcitonin |
| US4537716A (en) | 1983-12-05 | 1985-08-27 | Armour Pharmaceutical Co. | Des-serine2 or des-glycine2 -leucine22 calcitonin |
| FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
| US4604238A (en) | 1984-12-10 | 1986-08-05 | Armour Pharmaceutical Company | Analogs of calcitonin |
| US4606856A (en) | 1985-03-18 | 1986-08-19 | Seyler Jay K | [Des-1-amino, 8-glycine]calcitonin |
| US4652627A (en) | 1985-08-16 | 1987-03-24 | Kempe Tomas G | Calcitonin analogs with C-terminal D-amino acid substituents |
| US4687839A (en) | 1985-12-23 | 1987-08-18 | Kempe Tomas G | Calcitonin gene related peptide analogs with C-terminal D-amino acid substituents |
| US4697002A (en) | 1985-12-23 | 1987-09-29 | Kempe Tomas G | Calcitonin gene related peptide analogs with amino acid subdstituents at the penultimate position 36 |
| GB8709871D0 (en) | 1987-04-27 | 1987-06-03 | Turner R C | Peptides |
| US5175145A (en) * | 1988-08-26 | 1992-12-29 | Amylin Pharmaceuticals, Inc. | Treatment of diabetes mellitus with amylin agonists |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5405831A (en) | 1989-07-08 | 1995-04-11 | Amylin Pharmaceuticals, Inc. | Treatment of bone disorders |
| US5264372A (en) | 1991-03-15 | 1993-11-23 | Amylin Pharmaceuticals, Inc. | Receptor-based screening methods for amylin agonists and antagonists |
| US5234906A (en) * | 1991-01-10 | 1993-08-10 | Amylin Pharmaceuticals, Inc. | Hyperglycemic compositions |
| HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
| MD960317A (ro) | 1991-11-19 | 1998-05-31 | Anylin Pharmaceuticals, Inc. | Noile peptide-agoniste ale amilinei şi utilizarea lor |
| US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
| US6174530B1 (en) | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
| US6001364A (en) | 1993-05-05 | 1999-12-14 | Gryphon Sciences | Hetero-polyoxime compounds and their preparation by parallel assembly |
| US5589356A (en) | 1993-06-21 | 1996-12-31 | Vanderbilt University | Litigation of sidechain unprotected peptides via a masked glycoaldehyde ester and O,N-acyl rearrangement |
| DK0717635T3 (da) | 1993-09-07 | 2000-12-11 | Amylin Pharmaceuticals Inc | Fremgangsmåder til reduktion af gastrointestinal motilitet |
| US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6184344B1 (en) | 1995-05-04 | 2001-02-06 | The Scripps Research Institute | Synthesis of proteins by native chemical ligation |
| US5739106A (en) * | 1995-06-07 | 1998-04-14 | Rink; Timothy J. | Appetite regulating compositions |
| US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
| US5677279A (en) * | 1996-12-16 | 1997-10-14 | Amylin Pharmaceuticals, Inc. | Methods and compositions for treating pain with amylin or agonists thereof |
| US6307018B1 (en) | 1996-12-24 | 2001-10-23 | The Scripps Research Institute | General chemical ligation |
| CA2277112C (en) * | 1997-01-07 | 2008-08-26 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
| US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6410511B2 (en) | 1997-01-08 | 2002-06-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
| US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
| US7101853B2 (en) | 1997-05-06 | 2006-09-05 | Amylin Pharmaceuticals, Inc. | Method for treating or preventing gastritis using amylin or amylin agonists |
| US20040022807A1 (en) | 1998-06-05 | 2004-02-05 | Duft Bradford J | Methods for treating obesity |
| WO1998056807A1 (en) | 1997-06-13 | 1998-12-17 | Gryphon Sciences | Solid phase native chemical ligation of unprotected or n-terminal cysteine protected peptides in aqueous solution |
| DE69942453D1 (de) | 1998-05-29 | 2010-07-15 | Jgc Catalysts & Chemicals Ltd | Verfahren zur herstellung photoelektrischer zellen |
| US6087334A (en) | 1998-08-21 | 2000-07-11 | Amylin Pharmaceuticals, Inc. | Anti-diabetic peptides |
| DE69932249T2 (de) | 1998-08-31 | 2007-07-26 | Amylin Pharmaceuticals, Inc. (n.d.Ges.d. Staates Delaware), San Diego | Chemische anknüpfung unter einbeziehung von einer lipid-matrix und herstellung von membranpolypeptiden |
| US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
| TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
| US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
| US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
| US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
| TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
| US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
| MXPA03001469A (es) | 2000-09-08 | 2004-12-13 | Gryphon Therapeutics Inc | Proteinas sinteticas estimulantes de la eritropoyesis. |
| US7118737B2 (en) | 2000-09-08 | 2006-10-10 | Amylin Pharmaceuticals, Inc. | Polymer-modified synthetic proteins |
| US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
| GB0113657D0 (en) | 2001-06-05 | 2001-07-25 | Geneprot Inc | Improved native chemical ligation with three or more components |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| US20040138412A1 (en) | 2001-09-07 | 2004-07-15 | Paolo Botti | Extended native chemical ligation |
| WO2003042235A2 (en) | 2001-11-14 | 2003-05-22 | Geneprot, Inc. | Extended native chemical ligation of three or more peptide fragments |
| ES2316757T3 (es) | 2002-01-08 | 2009-04-16 | Amylin Pharmaceuticals, Inc. | Uso de agonistas de amilina para modular trigliceridos. |
| MY133587A (en) * | 2002-05-29 | 2007-11-30 | Glaxo Group Ltd | Aromatic sulfones and their medical use |
| WO2004007661A2 (en) | 2002-06-10 | 2004-01-22 | Geneprot, Inc. | Carboxy protection strategies for acidic c-terminal amino acids in chemical ligation of oligopeptides |
| US6965013B2 (en) | 2002-11-26 | 2005-11-15 | The Board Of Trustees Of The Leland Stanford Junior University | Intermedin and its uses |
| WO2004060925A2 (en) | 2002-12-30 | 2004-07-22 | Gryphon Therapeutics, Inc. | Multiplex polymer ligation |
| US20040197287A1 (en) * | 2003-04-04 | 2004-10-07 | The Procter & Gamble Company | Personal care composition containing an antidandruff component and a nonionic surfactant |
| EP1631597A4 (en) | 2003-05-22 | 2007-07-11 | Gryphon Therapeutics Inc | SOLID PHASE CHEMICAL LIGATION CARRIED OUT WITH A MOBILE BONDING AGENT |
| JP2008500281A (ja) | 2004-02-11 | 2008-01-10 | アミリン・ファーマシューティカルズ，インコーポレイテッド | アミリンファミリーペプチドおよびそれらを作成し使用するための方法 |
| US7399744B2 (en) * | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
| WO2006042242A2 (en) | 2004-10-08 | 2006-04-20 | Amylin Pharmaceuticals, Inc. | Amylin family polypeptide- 6 (afp- 6) analogs and methods of making and using them |
| BRPI0606466A2 (pt) | 2005-03-31 | 2009-06-30 | Amylin Pharmaceuticals Inc | amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos |
-
2006
- 2006-03-31 BR BRPI0606466-3A patent/BRPI0606466A2/pt not_active IP Right Cessation
- 2006-03-31 BR BRPI0609595A patent/BRPI0609595A8/pt not_active IP Right Cessation
- 2006-03-31 US US11/910,214 patent/US7879794B2/en not_active Expired - Fee Related
- 2006-03-31 MX MX2007012237A patent/MX2007012237A/es active IP Right Grant
- 2006-03-31 KR KR1020137025456A patent/KR20130122983A/ko not_active Ceased
- 2006-03-31 AU AU2006230602A patent/AU2006230602B2/en not_active Ceased
- 2006-03-31 KR KR1020077025124A patent/KR20080003849A/ko not_active Abandoned
- 2006-03-31 CN CN2006800192236A patent/CN101189021B/zh not_active Expired - Fee Related
- 2006-03-31 AT AT06740117T patent/ATE480255T1/de not_active IP Right Cessation
- 2006-03-31 US US11/910,206 patent/US7671023B2/en not_active Expired - Fee Related
- 2006-03-31 EP EP06749305A patent/EP1888094B1/en active Active
- 2006-03-31 NZ NZ561936A patent/NZ561936A/en not_active IP Right Cessation
- 2006-03-31 NZ NZ578298A patent/NZ578298A/en not_active IP Right Cessation
- 2006-03-31 EP EP06740117A patent/EP1871403B1/en active Active
- 2006-03-31 CA CA002602584A patent/CA2602584A1/en not_active Abandoned
- 2006-03-31 EP EP10008998.6A patent/EP2258382A3/en not_active Withdrawn
- 2006-03-31 WO PCT/US2006/011768 patent/WO2006105345A2/en not_active Ceased
- 2006-03-31 ES ES06749305T patent/ES2330671T3/es active Active
- 2006-03-31 AU AU2006230420A patent/AU2006230420B2/en not_active Ceased
- 2006-03-31 AT AT06749305T patent/ATE439140T1/de active
- 2006-03-31 JP JP2008504532A patent/JP5114381B2/ja not_active Expired - Fee Related
- 2006-03-31 KR KR1020077025152A patent/KR101383493B1/ko not_active Expired - Fee Related
- 2006-03-31 JP JP2008504396A patent/JP5415067B2/ja not_active Expired - Fee Related
- 2006-03-31 DK DK06749305T patent/DK1888094T3/da active
- 2006-03-31 NZ NZ578299A patent/NZ578299A/en not_active IP Right Cessation
- 2006-03-31 DE DE602006008456T patent/DE602006008456D1/de active Active
- 2006-03-31 CA CA002602261A patent/CA2602261A1/en not_active Abandoned
- 2006-03-31 EP EP10008733A patent/EP2248527A3/en not_active Withdrawn
- 2006-03-31 CN CN2011102204917A patent/CN102343084A/zh active Pending
- 2006-03-31 EA EA200702126A patent/EA013121B1/ru not_active IP Right Cessation
- 2006-03-31 MX MX2007012236A patent/MX2007012236A/es active IP Right Grant
- 2006-03-31 EP EP09009392.3A patent/EP2135617A3/en not_active Withdrawn
- 2006-03-31 DE DE602006016760T patent/DE602006016760D1/de active Active
- 2006-03-31 WO PCT/US2006/012601 patent/WO2006105527A2/en not_active Ceased
- 2006-10-04 CN CNA2006800541222A patent/CN101415435A/zh active Pending
-
2007
- 2007-09-24 IL IL186200A patent/IL186200A/en not_active IP Right Cessation
-
2009
- 2009-12-18 US US12/641,733 patent/US20100125054A1/en not_active Abandoned
-
2010
- 2010-12-09 US US12/964,516 patent/US8278267B2/en not_active Expired - Fee Related
-
2011
- 2011-05-20 US US13/112,290 patent/US8389477B2/en not_active Expired - Fee Related
-
2012
- 2012-09-28 US US13/631,577 patent/US20130225485A1/en not_active Abandoned
-
2013
- 2013-02-26 US US13/777,149 patent/US20130184213A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0606466A2 (pt) | amilina e agonistas de amilina para o tratamento de doenças e distúrbios psiquiátricos | |
| ECSP10010007A (es) | Tratamiento con ligandos alpha-7-selectivos | |
| CY1121135T1 (el) | Ενωσεις υποκατεστημενης τετρακυκλιnhς για την θεραπευτικη αγωγη φλεγμονωδων διαταραχων του δερματος | |
| SG170813A1 (en) | New compounds | |
| NO20074943L (no) | Roflumilast for behandlingen av diabetes mellitus | |
| UA109878C2 (uk) | Похідні ізохінолінону, фармацевтична композиція на їх основі (варіанти) та спосіб лікування захворювань (варіанти) | |
| MX2009004047A (es) | Compuestos organicos. | |
| NO20083002L (no) | Fremgangsmate for anvendelse av CD40-bindende forbindelser | |
| WO2008008887A3 (en) | Gpr119 agonists for treating metabolic disorders | |
| BR112021025537A2 (pt) | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica | |
| BRPI0812889A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para o tratamento ou prevenção de distúrbios neurológicos e psiquiátricos associados com a disfunção de glutamato em um animal. | |
| ATE528002T1 (de) | Pyridoncarboxamidderivate zur behandlung hyperproliferativer und angiogenese-vermittelter leiden | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| CY1110046T1 (el) | Γαβοξαδολη για τη θεραπεια της καταθλιψης και αλλων συναισθηματικων διαταραχων | |
| BRPI0712607A8 (pt) | métodos de tratamento de acidente vascular cerebral | |
| WO2007053622A3 (en) | Methods for modulating ppar activity to treat diseases caused by mutations in the cftr gene | |
| NO20081835L (no) | Behandlingsmetoder ved bruk av oksytocin receptoragonister | |
| AU2007268684A8 (en) | Anti-foot-and-mouth disease virus agent for animal belonging to family Suidae or sheep, and method for prevention or treatment of foot-and-mouth disease in animal belonging to family Suidae or sheep | |
| EA200900425A1 (ru) | Способ повышения толерантности растений | |
| BRPI0823317A2 (pt) | "método e aparelho para fabricação de componente para cabeça de navalhas, e componentes fabricados desta forma".' | |
| CY1116166T1 (el) | Νεα μεθοδος για την αντιμετωπιση λοιμωξεων απο η.pylori | |
| DE602006012313D1 (de) | Kombination aus pyrimidylaminobenzamid-verbindungen und imatinib zur behandlung oder verhinderung proliferativer erkrankungen | |
| WO2006065968A3 (en) | The uses of estrogen beta agonists to treat cognitive diseases | |
| CY1116330T1 (el) | Αναλογα 2-αμινοπυριδινης ως ενεργοποιητες γλυκοκινασης | |
| UY29237A1 (es) | Metodos detratamiento y prevencion |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B06H | Technical and formal requirements: requirement cancelled [chapter 6.8 patent gazette] |
Free format text: REF. A RPI NO 2154 DE 17/04/2012. ANULACAO DA EXIGENCIA 6.6 POR TER SIDO INDEVIDA. REQUERENTE NAO APRESENTOU RESPOSTA A EXIGENCIA CONFORME DISPOE A RESOLUCAO 207 DE 24/04/2009, ENTRETANTO, A RESPOSTA CONSTA NO FORMULARIO DE DEPOSITO. |
|
| B25D | Requested change of name of applicant approved |
Owner name: AMYLIN PHARMACEUTICALS, LLC (US) |
|
| B25A | Requested transfer of rights approved |
Owner name: ASTRAZENECA PHARMACEUTICALS LP (US) |
|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 10A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |